Literature DB >> 33505688

Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome.

Tamer Mohamed Zaalouk1, Zouheir Ibrahim Bitar1, Ossama Sajeh Maadarani1, Mohamed Elsayed Elhabibi1.   

Abstract

Stevens-Johnson syndrome (SJS) is serious conditions that happen as a result of infection, side effects to medications, or unknown etiology. Carbamazepine is one of the common medications that can cause SJS. Good history taking is crucial if treatment with carbamazepine is clinically indicated. We would like to alert all physicians that carbamazepine should be avoided in any patient with a previous history of drug reaction such as mast cell activation syndrome.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Stevens‐Johnson syndrome; carbamazepine; mast cell activation syndrome; methotrexate

Year:  2020        PMID: 33505688      PMCID: PMC7813119          DOI: 10.1002/ccr3.3509

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


  17 in total

1.  Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study.

Authors:  Nicole Mittmann; Sandra R Knowles; Marika Koo; Neil H Shear; Anita Rachlis; Sean B Rourke
Journal:  Am J Clin Dermatol       Date:  2012-02-01       Impact factor: 7.403

2.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

Review 3.  Mast Cells, Mastocytosis, and Related Disorders.

Authors:  Theoharis C Theoharides; Peter Valent; Cem Akin
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

4.  Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  B Rzany; O Hering; M Mockenhaupt; W Schröder; E Goerttler; J Ring; E Schöpf
Journal:  Br J Dermatol       Date:  1996-07       Impact factor: 9.302

5.  A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  P Wolkenstein; V Carrière; D Charue; S Bastuji-Garin; J Revuz; J C Roujeau; P Beaune; M Bagot
Journal:  Pharmacogenetics       Date:  1995-08

6.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

Review 7.  Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme.

Authors:  J C Roujeau
Journal:  J Dermatol       Date:  1997-11       Impact factor: 4.005

8.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Peggy Sekula; Ariane Dunant; Maja Mockenhaupt; Luigi Naldi; Jan Nico Bouwes Bavinck; Sima Halevy; Sylvia Kardaun; Alexis Sidoroff; Yvonne Liss; Martin Schumacher; Jean-Claude Roujeau
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551

9.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

Review 10.  Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.

Authors:  Adam Rotunda; Ranella J Hirsch; Noah Scheinfeld; Jeffrey M Weinberg
Journal:  Acta Derm Venereol       Date:  2003       Impact factor: 4.437

View more
  1 in total

1.  The Co-Existence of Agranulocytosis and Stevens-Johnson Syndrome (SJS) in Carbamazepine Therapy: A Case Report.

Authors:  Saima Batool; Diana Voloshyna; Muhammad Usama; Muhammad Suleman; Qudsia I Sandhu; Laxman Nepal; Naglaa G Ghobriel; Jaina Mengar; Ahmed Soodod Mohammed Rasmy
Journal:  Cureus       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.